lenalidomide
Not Tagged
[' lena', 'myeloma xi']
great #ash22 presentation by with more interesting data generated by the myeloma xi trial. benefit of lenalidomode maintenance post asct maintained for all patients with at least 4-5 years of treatment and with at least 3 years if sustained mrd negativity.
Consultant Haematologist. Interested in haemato-oncology in general and multiple myeloma in particular.